Blaubeuren

Obstructive sleep apnea (OSA) occurs when muscles in the throat relax during sleep, causing the tongue to fall back and the airway to narrow or collapse. This limits airflow, leading to snoring or complete pauses in breathing called obstructive apneas. OSA can cause daytime sleepiness and increase risks such as car accidents and cardiovascular problems. The first-line treatment is positive airway pressure (PAP), which uses a mask to keep airways open, but some patients cannot tolerate this therapy. As an alternative, mandibular advancement devices (MADs) are studied for their potential to improve airway volume by moving the lower jaw forward during sleep. This registry study evaluates how MADs are prescribed and used in real-life settings for patients with OSA. It collects information on patient characteristics, reasons for stopping therapy, side effects, and how therapy costs are shared between patients and insurance providers. The study monitors changes in the Apnoea-Hypopnea-Index (AHI) from baseline to 3 months after treatment to assess therapy impact. Participants will be followed for at least 3 months after receiving MAD therapy. Researchers will record patient data, side effects, and therapy usage patterns. The study aims to understand patient pathways, therapy adherence, and factors influencing the success of MAD treatment for OSA. This includes tracking safety and efficacy outcomes as well as therapy compliance over the observation period.

Ulcerative colitis (UC) is an inflammatory bowel disease causing inflammation and bleeding in the rectum and colon. This research evaluates the effectiveness of upadacitinib (RINVOQ), an approved treatment for UC, in adults with active moderate to severe UC. The study aims to understand the early therapeutic response and predict the long-term effectiveness of this medication. Upadacitinib will be given according to the approved local label and prescribed by the participant's physician as part of routine care. About 400 adult participants from Germany, Austria, and Switzerland who are starting upadacitinib treatment will be enrolled. Treatment decisions are made by the investigator independently of the study. Participants will be followed for up to two years, with no extra procedures beyond their standard care. During the study, participants will attend regular hospital or clinic visits where routine data will be collected and used for the study. Researchers will monitor the percentage of participants achieving symptomatic remission based on clinical response and intestinal ultrasound at week 8, with follow-up assessments at week 52. The study focuses on real-world treatment outcomes without adding extra burden to participants.